Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Siremadlin succinate by Novartis for Secondary Acute Myeloid Leukemia: Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Secondary Acute Myeloid Leukemia. According to...
Siremadlin succinate by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Siremadlin succinate by Novartis for Metastatic Colorectal Cancer: Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
Siremadlin succinate by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to...
Siremadlin succinate by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According...
Siremadlin succinate by Novartis for Myelofibrosis: Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...